| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/10/2004 | US6689398 Triterpene compositions and methods for use thereof |
| 02/10/2004 | US6689384 Stable pergolide mesylate and process for making same |
| 02/10/2004 | US6689381 Liposome comprising phosphatidylcholine, cholesterol, as well as benzoquinazoline thymidylate synthase inhibitor; improved pharmacokinetics and efficacy as anti-tumor agents compared to free drug |
| 02/10/2004 | US6689359 Ligands, including antibodies, showing reactivity against endocrine cells |
| 02/10/2004 | US6689355 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 02/10/2004 | US6689353 Stabilized with histidine, glycine and sucrose |
| 02/10/2004 | US6689352 Polypeptide |
| 02/10/2004 | US6689351 Use of GM-CSF to promote accelerated wound healing |
| 02/10/2004 | US6689338 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 02/10/2004 | CA2291975C Quaternary ammonium compounds |
| 02/10/2004 | CA2274581C Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
| 02/10/2004 | CA2274381C Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 |
| 02/10/2004 | CA2262652C Anti-stress drugs and functional foods having anti-stress effects |
| 02/10/2004 | CA2223551C Benzimidazole compounds |
| 02/10/2004 | CA2164951C Lipoxin compounds |
| 02/10/2004 | CA2134196C Pharmaceutical preparation and process for its manufacture |
| 02/10/2004 | CA2114936C Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones |
| 02/10/2004 | CA2108903C Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| 02/09/2004 | CA2421269A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/05/2004 | WO2004011662A1 Persulfated oligosaccharide acting on selectins and chemokine |
| 02/05/2004 | WO2004011661A1 Novel physiologically active substances |
| 02/05/2004 | WO2004011651A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | WO2004011640A1 Three-dimensional structure of dipeptidyl peptidase iv |
| 02/05/2004 | WO2004011637A2 Modified adamts4 molecules and method of use thereof |
| 02/05/2004 | WO2004011632A2 Oligodendrocyte production from multipotent neural stem cells |
| 02/05/2004 | WO2004011625A2 Polymorphisms for predicting disease and treatment outcome |
| 02/05/2004 | WO2004011611A2 Taci antibodies and uses thereof |
| 02/05/2004 | WO2004011495A1 Brca1-interacting protein |
| 02/05/2004 | WO2004011481A1 Phosmidosine derivative and process for producing the same |
| 02/05/2004 | WO2004011476A1 Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer |
| 02/05/2004 | WO2004011470A1 Furoisoquinoline derivative and use thereof |
| 02/05/2004 | WO2004011469A1 Cell differentiation inductor |
| 02/05/2004 | WO2004011465A1 Kinase inhibitors |
| 02/05/2004 | WO2004011459A1 Novel physiologically active substance |
| 02/05/2004 | WO2004011444A2 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives |
| 02/05/2004 | WO2004011443A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 02/05/2004 | WO2004011442A1 Pyrimidine derivatives |
| 02/05/2004 | WO2004011432A1 Organic acid salt of amlodipine |
| 02/05/2004 | WO2004011430A1 Sodium channel inhibitor |
| 02/05/2004 | WO2004011410A1 Chemical compounds |
| 02/05/2004 | WO2004011402A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | WO2004011069A1 Medicament dispenser |
| 02/05/2004 | WO2004011067A1 Medicament dispenser |
| 02/05/2004 | WO2004011030A1 Medicinal composition for treating thrombopenia |
| 02/05/2004 | WO2004011028A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 02/05/2004 | WO2004011010A1 Myocardial perfusion imaging using a2a receptor agonists |
| 02/05/2004 | WO2004011006A1 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 02/05/2004 | WO2004011002A1 Sustained-release tablet composition comprising a dopamine receptor agonist |
| 02/05/2004 | WO2004011001A1 Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 02/05/2004 | WO2004010999A1 Pramipexole once-daily dosage form |
| 02/05/2004 | WO2004010997A1 Sustained-release tablet composition of pramipexole |
| 02/05/2004 | WO2004010996A1 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis |
| 02/05/2004 | WO2004010995A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 02/05/2004 | WO2004010993A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 02/05/2004 | WO2004010991A1 Food improving blood flow |
| 02/05/2004 | WO2004010990A1 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |
| 02/05/2004 | WO2004010987A2 Use of s1p receptor agonists in heart diseases |
| 02/05/2004 | WO2004010980A1 Compositions comprising hmg-coa reductase inhibitor |
| 02/05/2004 | WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | WO2004010972A2 Pellicle-resistant gelatin capsule |
| 02/05/2004 | WO2004010950A2 Aryl substituted hydantoin compounds and their use as sodium channel blockers |
| 02/05/2004 | WO2004010945A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | WO2003097644A3 Non-nucleoside reverse transcriptase inhibitors |
| 02/05/2004 | WO2003087818A3 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 02/05/2004 | WO2003084560A3 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 02/05/2004 | WO2003080580A3 Quinoline derivatives and their use as 5-ht6 ligands |
| 02/05/2004 | WO2003075857A3 Amino-methyl substituted tetracycline compounds |
| 02/05/2004 | WO2003074654A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 02/05/2004 | WO2003074062A3 Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals |
| 02/05/2004 | WO2003066091A3 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 02/05/2004 | WO2003064455A3 Macrocyclic peptides active against the hepatitis c virus |
| 02/05/2004 | WO2003064388A3 Process for the preparation of high purity perindopril and intermediates useful in the synthesis |
| 02/05/2004 | WO2003024354A3 Interleukin-12 as a veterinary vaccine adjuvant |
| 02/05/2004 | WO2003020947A3 Mid 9002, a human sulfatase family member and uses therefor |
| 02/05/2004 | WO2002100886A8 Pyrrolidin-2-one derivatives as inhibitors of factor xa |
| 02/05/2004 | WO2002041834A8 Atorvastatin hemi-calcium form vii |
| 02/05/2004 | US20040024220 Lipids |
| 02/05/2004 | US20040024218 Novel compounds |
| 02/05/2004 | US20040024217 Synthesis of piperidine and piperazine compounds as CCR5 antagonists |
| 02/05/2004 | US20040024215 Such as 4'-trifluoromethyl-biphenyl-2-carboxylic acid(4-(4-(alpha-methyl-benzyl)-piperazin-1-yl)-phenyl)-amide; apoprotein B-100 (apoB-100) and microsomal triglyceride transfer protein (MTP) |
| 02/05/2004 | US20040024211 Such as (3S)-N-(2-(2-(2,4-dichlorophenyl)ethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl) -3-methyl-N'-((1S,2S,3S,5R)-2,6,6-trimethylbicyclo(3.1.1)hept-3 -yl)piperazine-1-carboximidamide for treatment of obesity or type II diabetes |
| 02/05/2004 | US20040024210 New compounds |
| 02/05/2004 | US20040024208 Cyclic protein tyrosine kinase inhibitors |
| 02/05/2004 | US20040024207 8'4-'3-(5Fluoro-1h-indol-3yl)propyl!-1-piperazinyl!-2-methyl-2h-1,4-benzoxazin-3(4h)-one methanesulfonate with high affinity for the dopamine d2 receptor and the seotonix reuptake site |
| 02/05/2004 | US20040024190 Viral polymerase inhibitors |
| 02/05/2004 | US20040024179 Comprises peptide with heparin and/or lipopolysaccharide binding activity for use as treatment of endotoxic shock and endometriosis, anticoagulant, angiogenesis inhibitor, antiproliferative agent and contraceptive |
| 02/05/2004 | US20040024066 E.g., N-(2-(Benzo(b)thiophen-5-ylmethanesulfonyl)-1-(3,4-dichloro- phenyl)- ethyl)-N-hydroxyformamide; gene expression inhibitors of s-CD23; autoimmune disease; antiallergens; matrix metalloprotease enzyme inhibitors |
| 02/05/2004 | US20040024063 Fatty acid analogues for the treatment of cancer |
| 02/05/2004 | US20040024060 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/05/2004 | US20040024057 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications |
| 02/05/2004 | US20040024056 Especially Cryptotanshinone and Dihydortanshinone; treatment of chronic hepatitis and hepatocirrhosis |
| 02/05/2004 | US20040024049 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 02/05/2004 | US20040024044 In chemoprevention of estrogen dependent cancer in mammals, including humans |
| 02/05/2004 | US20040024043 Administering (-)N-(-)-N phenyl canbamoyleseroline; Alzheimer's disease |
| 02/05/2004 | US20040024041 Dermal therapeutic system containing non-steroidal antiphlogistics with selective cox-2 inhibition |
| 02/05/2004 | US20040024040 Inhibitors of GSK-3 and uses thereof |
| 02/05/2004 | US20040024039 Having a steroid C17,20-lyase inhibitory activity; useful as prophylactic or therapeutic agent for prostate and breast cancers |
| 02/05/2004 | US20040024038 GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| 02/05/2004 | US20040024036 May take form of gel, ointment or emulsion for local administration, of transdermal patch or of film deposited by a spray, characterized in that it comprises at least one absorption promoter |